In the context of SMARCA4 NSCLC patients treated with immune checkpoint inhibitors (ICIs), one study found that those with SMARCA4 mutations had worse outcomes than WT patients regardless of ICI treatment or not (HR = 3.2; p = 0.006), and two separate OAK trial NSCLC analyses showed no OS differences with atezolizumab (ICI) vs. docetaxel in pre-treated NSCLC SMARCA4-mutated patients [27,28,29]. Here, SMARCA4 is linked to non-small cell lung carcinoma.